{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:44:28Z","timestamp":1792421068509,"version":"4.5.0"},"reference-count":62,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jac\/dky286","type":"journal-article","created":{"date-parts":[[2018,6,24]],"date-time":"2018-06-24T07:09:19Z","timestamp":1529824159000},"source":"Crossref","is-referenced-by-count":118,"title":["European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia"],"prefix":"10.1093","author":[{"given":"Johan A","family":"Maertens","sequence":"first","affiliation":[{"name":"Department of Haematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Girmenia","sequence":"additional","affiliation":[{"name":"Department of Haematology, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F","family":"Duarte","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C","family":"Kibbler","sequence":"additional","affiliation":[{"name":"Centre for Medical Microbiology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Division of Haematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Racil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Haematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ribaud","sequence":"additional","affiliation":[{"name":"Quality Unit, P\u00f4le Pr\u00e9Bloc, Saint-Louis and Lariboisi\u00e8re Hospital Group, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A","family":"Slavin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, Australia"},{"name":"Department of Medicine, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany"},{"name":"Clinical Trials Centre Cologne (ZKS K\u00f6ln), Cologne, Germany"},{"name":"Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Peter Donnelly","sequence":"additional","affiliation":[{"name":"Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"Hopital Henri Mondor, Assistance Publique-H\u00f4pitaux de Paris, Department of Haematology, Cr\u00e9teil, France"},{"name":"Universit\u00e9 Paris-Est-Cr\u00e9teil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"European Conference on Infections in Leukaemia (ECIL)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"key\n\t\t\t\t20180802013026_dky286-B1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejcsup.2007.06.001","article-title":"The first European Conference on Infections in Leukaemia: why and how?","volume":"5","author":"Cordonnier","year":"2007","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180802013026_dky286-B2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejcsup.2007.06.006","article-title":"Primary antifungal prophylaxis in leukaemia patients","volume":"5","author":"Maertens","year":"2007","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180802013026_dky286-B3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B4","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1470-2045(14)70017-8","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation","volume":"15","author":"Groll","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B5","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network 2005\u20132007","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180802013026_dky286-B6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2012.220","article-title":"Supportive care in severe and very severe aplastic anemia","volume":"48","author":"H\u00f6chsmann","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2011.178","article-title":"ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients","volume":"47","author":"Marchetti","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jcp.52.5.376","article-title":"Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology","volume":"52","author":"Huijgens","year":"1999","journal-title":"J Clin Pathol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7326\/0003-4819-118-7-199304010-00003","article-title":"Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial","volume":"118","author":"Winston","year":"1993","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180802013026_dky286-B11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B12","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180802013026_dky286-B13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180802013026_dky286-B14","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t20180802013026_dky286-B15","first-page":"9","article-title":"Laminar air flow rooms: use for patients with leukemia","volume":"11","author":"Bodey","year":"1972","journal-title":"Contam Control"},{"key":"key\n\t\t\t\t20180802013026_dky286-B16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/503435","article-title":"The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review","volume":"193","author":"Eckmanns","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/IAI.01359-15","article-title":"Polymorphisms in host immunity-modulating genes and risk of invasive aspergillosis: results from the AspBIOmics Consortium","volume":"84","author":"Lupia\u00f1ez","year":"2015","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180802013026_dky286-B18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2014.113399","article-title":"Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)","volume":"100","author":"Caira","year":"2015","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180802013026_dky286-B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1749-6632.2012.06829.x","article-title":"Risk stratification for invasive aspergillosis in immunocompromised patients","volume":"1272","author":"Herbrecht","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t20180802013026_dky286-B20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B21","author":"Donnelly"},{"key":"key\n\t\t\t\t20180802013026_dky286-B22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bmt.2009.261","article-title":"Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated","volume":"44","author":"Yokoe","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1086\/313654","article-title":"A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients","volume":"30","author":"Nucci","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10428199309067926","article-title":"Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study","volume":"115\u20136","author":"Vreugdenhil","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20180802013026_dky286-B26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jac\/dki440","article-title":"An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia","volume":"57","author":"Glasmacher","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B27","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1128\/AAC.44.7.1887-1893.2000","article-title":"Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B","volume":"44","author":"Harousseau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B29","doi-asserted-by":"crossref","first-page":"e2560.","DOI":"10.1097\/MD.0000000000002560","article-title":"Does high-dose cytarabine cause more fungal infection in patients with acute myeloid leukemia undergoing consolidation therapy","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t20180802013026_dky286-B30","doi-asserted-by":"crossref","first-page":"1747.","DOI":"10.1093\/jac\/dkw079","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B31","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B32","doi-asserted-by":"crossref","first-page":"3610.","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B33","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/jac\/dkq441","article-title":"Optimizing management of invasive mould diseases","volume":"66","author":"Agrawal","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B34","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","article-title":"Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP","volume":"60","author":"Lempers","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180802013026_dky286-B37","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/jac\/dks266","article-title":"Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation","volume":"67","author":"Herbrecht","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180802013026_dky286-B38","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180802013026_dky286-B39","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.ijid.2012.09.004","article-title":"Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005\u20132009","volume":"17","author":"Racil","year":"2013","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180802013026_dky286-B41","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180802013026_dky286-B42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20180802013026_dky286-B43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180802013026_dky286-B44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12094-012-0767-5","article-title":"Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations","volume":"14","author":"Pajares","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B45","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B46","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180802013026_dky286-B47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B48","doi-asserted-by":"crossref","first-page":"e2012070.","DOI":"10.4084\/mjhid.2012.070","article-title":"Infectious complications in chronic lymphocytic leukemia","volume":"4","author":"Nosari","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/1469-0691.12014","article-title":"Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections","volume":"19","author":"Nosari","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180802013026_dky286-B50","first-page":"1145","article-title":"Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes","volume":"90","author":"Molteni","year":"2005","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t20180802013026_dky286-B51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bmt.2008.303","article-title":"Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT","volume":"43","author":"Gil","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1600-0609.2005.00605.x","article-title":"Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients","volume":"76","author":"Jantunen","year":"2006","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0609.2004.00273.x","article-title":"Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients","volume":"73","author":"Jantunen","year":"2004","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B54","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbmt.2014.03.004","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"20","author":"Girmenia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajic.2016.08.003","article-title":"Could we predict airborne Aspergillus contamination during construction work?","volume":"45","author":"Pilmis","year":"2017","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t20180802013026_dky286-B56","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.bbmt.2016.06.008","article-title":"Risk factors for invasive mold infections and implications for choice of prophylaxis after allogeneic stem cell transplantation","volume":"22","author":"Blennow","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20180802013026_dky286-B57","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180802013026_dky286-B58","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180802013026_dky286-B60","author":"Cornely"},{"key":"key\n\t\t\t\t20180802013026_dky286-B61","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: a new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180802013026_dky286-B62","author":"ESCMID guidelines for diagnosis and treatment of Aspergillus diseases"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dky286\/25403622\/dky286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T18:40:16Z","timestamp":1571510416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky286\/5063539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1093\/jac\/dky286","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733770214.793549705","asserted-by":"object"}]},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}